Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 63,156 |
Reported balance
After 2023-02-28 transaction · row 1
1 source rowRow 1 · 2023-02-28 · Tax withholding · Disposed 3,522 · Balance 63,156 |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 75 |
Reported balance
Holding disclosure · report date 2023-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 75 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 3, 2023 00:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,522 | $99.77 | $351,389.94 |
DisclosureSEC source: 0001415889-23-003914 · form4-03032023_120318.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,156 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,628 | $122.41 | $566,513.48 |
DisclosureSEC source: 0001415889-22-002199 · form4-03022022_040307.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,678 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 40,710 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001745 · form4-02232022_050219.xml · derivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,710 Underlying: Common Shares · 40,710 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,570 on February 18, 2023, 13,570 on February 18, 2024, and 13,570 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 8,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001745 · form4-02232022_050219.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,306 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001415889-21-004350 · form4-09102021_030923.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,008 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,008 | $129.05 | $2,969,173.20 |
DisclosureSEC source: 0001415889-21-004350 · form4-09102021_030923.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,571 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.03 to $129.09, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,008 | $50.72 | $1,166,965.76 |
DisclosureSEC source: 0001415889-21-004350 · form4-09102021_030923.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,246 | $121.58 | $759,388.68 |
DisclosureSEC source: 0001415889-21-001211 · form4-03022021_040319.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,571 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 47,993 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000898 · form4-02232021_040257.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Underlying: Common Shares · 47,993 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,997 on February 19, 2022, 15,998 on February 19, 2023, and 15,998 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000898 · form4-02232021_040257.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,817 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 02, 2021 Filed Feb 24, 2021 00:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000898 · form4-02232021_040257.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,454 Read SEC document |
| December 21, 2020 Filed Dec 31, 2020 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | OtherCommon shares without par value | 75 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-003073 · form4-12312020_021212.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 75 Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002993 · form4-12182020_041240.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,454 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,008 Underlying: Common shares · 23,008 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,437 | $99.08 | $241,457.96 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · nonDerivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,454 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,008 | $98.00 | $2,254,784.00 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,891 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,176 | $79.19 | $330,697.44 |
DisclosureSEC source: 0001179110-20-002916 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,891 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 76,198 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002287 · edgar.xml · derivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,198 Underlying: Common shares · 76,198 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,399 on February 21, 2021, 25,399 on February 21, 2022, and 25,400 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002287 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,067 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 471 | $89.66 | $42,229.86 |
DisclosureSEC source: 0001179110-20-001887 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,567 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,182 | $86.80 | $623,397.60 |
DisclosureSEC source: 0001179110-20-000212 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,038 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,016 Underlying: Common shares · 23,008 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · nonDerivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,220 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,008 | $86.39 | $1,987,704.84 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,220 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.32 to $86.44, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,008 | $50.72 | $1,166,965.76 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2019 Filed Jul 23, 2019 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,437 | $87.49 | $213,213.13 |
DisclosureSEC source: 0001179110-19-008774 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,220 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,094 | $77.23 | $161,719.62 |
DisclosureSEC source: 0001179110-19-003122 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,657 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 72,513 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002646 · edgar.xml · derivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,513 Underlying: Common shares · 72,513 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,171 on February 22, 2020, 24,171 on February 22, 2021, and 24,171 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002646 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,751 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 505 | $75.25 | $38,001.25 |
DisclosureSEC source: 0001179110-19-002155 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,918 Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 450 | $75.25 | $33,862.50 |
DisclosureSEC source: 0001179110-19-002155 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,423 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,544 | $71.09 | $394,122.96 |
DisclosureSEC source: 0001179110-19-000290 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,873 Read SEC document |
| July 24, 2018 Filed Jul 24, 2018 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 803 | $63.50 | $50,990.50 |
DisclosureSEC source: 0001179110-18-009886 · edgar.xml · nonDerivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,417 Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 247 | $63.20 | $15,610.40 |
DisclosureSEC source: 0001179110-18-009886 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,220 Read SEC document |
| July 21, 2018 Filed Jul 24, 2018 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,637 | $63.32 | $103,654.84 |
DisclosureSEC source: 0001179110-18-009886 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,467 Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 504 | $60.99 | $30,738.96 |
DisclosureSEC source: 0001179110-18-009370 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,104 Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 461 | $59.92 | $27,623.12 |
DisclosureSEC source: 0001179110-18-005310 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,608 Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 459 | $59.29 | $27,212.73 |
DisclosureSEC source: 0001179110-18-002505 · edgar.xml · nonDerivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,069 Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 571 | $60.17 | $34,357.07 |
DisclosureSEC source: 0001179110-18-002505 · edgar.xml · nonDerivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,528 Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 487 | $60.17 | $29,302.79 |
DisclosureSEC source: 0001179110-18-002505 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,099 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002505 · edgar.xml · derivative · entry 5 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002505 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,586 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,631 | $57.07 | $150,151.17 |
DisclosureSEC source: 0001179110-18-000341 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,556 Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 69,024 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-17-010666 · edgar.xml · derivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,024 Underlying: Common shares · 69,024 shares Expires 2027-07-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,008 on 07/21/2018, 23,008 on 07/21/2019, and 23,008 on 07/21/2020. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010666 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,187 F2 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, vesting in annual increments of 3,334 on 07/21/2018, 3,333 on 07/21/2019, and 3,333 on 07/21/2020. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 6,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010666 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,187 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.